Connection

LUHUA WANG to Mice

This is a "connection" page, showing publications LUHUA WANG has written about Mice.
Connection Strength

0.284
  1. Strategic Therapeutic Targeting to Overcome Venetoclax Resistance in Aggressive B-cell Lymphomas. Clin Cancer Res. 2018 08 15; 24(16):3967-3980.
    View in: PubMed
    Score: 0.036
  2. In vitro and in vivo therapeutic efficacy of carfilzomib in mantle cell lymphoma: targeting the immunoproteasome. Mol Cancer Ther. 2013 Nov; 12(11):2494-504.
    View in: PubMed
    Score: 0.026
  3. Combination of atiprimod and the proteasome inhibitor bortezomib induces apoptosis of mantle cell lymphoma in vitro and in vivo. Leuk Res. 2012 Mar; 36(3):363-8.
    View in: PubMed
    Score: 0.023
  4. Lenalidomide synergizes with dexamethasone to induce growth arrest and apoptosis of mantle cell lymphoma cells in vitro and in vivo. Leuk Res. 2011 Mar; 35(3):380-6.
    View in: PubMed
    Score: 0.022
  5. Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo. Am J Hematol. 2009 Sep; 84(9):553-9.
    View in: PubMed
    Score: 0.020
  6. A severe combined immunodeficient-hu in vivo mouse model of human primary mantle cell lymphoma. Clin Cancer Res. 2008 Apr 01; 14(7):2154-60.
    View in: PubMed
    Score: 0.018
  7. Bortezomib is synergistic with rituximab and cyclophosphamide in inducing apoptosis of mantle cell lymphoma cells in vitro and in vivo. Leukemia. 2008 Jan; 22(1):179-85.
    View in: PubMed
    Score: 0.017
  8. Atiprimod inhibits the growth of mantle cell lymphoma in vitro and in vivo and induces apoptosis via activating the mitochondrial pathways. Blood. 2007 Jun 15; 109(12):5455-62.
    View in: PubMed
    Score: 0.017
  9. Gene mutations in primary tumors and corresponding patient-derived xenografts derived from non-small cell lung cancer. Cancer Lett. 2015 Feb 01; 357(1):179-185.
    View in: PubMed
    Score: 0.007
  10. Selective antitumor activity of ibrutinib in EGFR-mutant non-small cell lung cancer cells. J Natl Cancer Inst. 2014 Sep; 106(9).
    View in: PubMed
    Score: 0.007
  11. Osteoblastic niche supports the growth of quiescent multiple myeloma cells. Blood. 2014 Apr 03; 123(14):2204-8.
    View in: PubMed
    Score: 0.007
  12. Antigen presenting cell-mediated expansion of human umbilical cord blood yields log-scale expansion of natural killer cells with anti-myeloma activity. PLoS One. 2013; 8(10):e76781.
    View in: PubMed
    Score: 0.007
  13. Evidence of a role for CD44 and cell adhesion in mediating resistance to lenalidomide in multiple myeloma: therapeutic implications. Leukemia. 2014 Feb; 28(2):373-83.
    View in: PubMed
    Score: 0.006
  14. Novel selective inhibitors of nuclear export CRM1 antagonists for therapy in mantle cell lymphoma. Exp Hematol. 2013 Jan; 41(1):67-78.e4.
    View in: PubMed
    Score: 0.006
  15. Role of the microenvironment in mantle cell lymphoma: IL-6 is an important survival factor for the tumor cells. Blood. 2012 Nov 01; 120(18):3783-92.
    View in: PubMed
    Score: 0.006
  16. Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma. Blood. 2012 Oct 18; 120(16):3260-70.
    View in: PubMed
    Score: 0.006
  17. Calcium blockers decrease the bortezomib resistance in mantle cell lymphoma via manipulation of tissue transglutaminase activities. Blood. 2012 Mar 15; 119(11):2568-78.
    View in: PubMed
    Score: 0.006
  18. HDM-2 inhibition suppresses expression of ribonucleotide reductase subunit M2, and synergistically enhances gemcitabine-induced cytotoxicity in mantle cell lymphoma. Blood. 2011 Oct 13; 118(15):4140-9.
    View in: PubMed
    Score: 0.006
  19. Targeting cell surface ?2 -microglobulin by pentameric IgM antibodies. Br J Haematol. 2011 Jul; 154(1):111-21.
    View in: PubMed
    Score: 0.006
  20. Luteinizing Hormone-Releasing Hormone (LHRH)-I antagonist cetrorelix inhibits myeloma cell growth in vitro and in vivo. Mol Cancer Ther. 2011 Jan; 10(1):148-58.
    View in: PubMed
    Score: 0.005
  21. Prospective isolation of clonogenic mantle cell lymphoma-initiating cells. Stem Cell Res. 2010 Nov; 5(3):212-25.
    View in: PubMed
    Score: 0.005
  22. Myeloma cell line-derived, pooled heat shock proteins as a universal vaccine for immunotherapy of multiple myeloma. Blood. 2009 Oct 29; 114(18):3880-9.
    View in: PubMed
    Score: 0.005
  23. Annexin A2 is involved in antiphospholipid antibody-mediated pathogenic effects in vitro and in vivo. Blood. 2009 Oct 01; 114(14):3074-83.
    View in: PubMed
    Score: 0.005
  24. Human C-reactive protein binds activating Fcgamma receptors and protects myeloma tumor cells from apoptosis. Cancer Cell. 2007 Sep; 12(3):252-65.
    View in: PubMed
    Score: 0.004
  25. Dickkopf-1 (DKK1) is a widely expressed and potent tumor-associated antigen in multiple myeloma. Blood. 2007 Sep 01; 110(5):1587-94.
    View in: PubMed
    Score: 0.004
  26. Targeting beta2-microglobulin for induction of tumor apoptosis in human hematological malignancies. Cancer Cell. 2006 Oct; 10(4):295-307.
    View in: PubMed
    Score: 0.004
  27. Retinoid receptor-dependent and -independent effects of N-(4-hydroxyphenyl)retinamide in F9 embryonal carcinoma cells. Cancer Res. 1999 Jan 01; 59(1):14-8.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.